65,437 trials
Dry Eye Syndromes
Primary: Aqueous Humor Flare — 8.4; 9.3; 11.4; 8.4 photons/msec
Contact Lens Fit · Myopia
Primary: Lens Fit — 100; 100 percentage of acceptable fit
Open-angle Glaucoma · Ocular Hypertension
Primary: Adherence — 63; 43 percentage of adherent patients
Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Objective Response Rate Assessed by RECIST Criteria. — 0; 3; 5; 9 participants
Lip Enhancement
Primary: Investigator Assessment of the Subject's Overall Lip Fullness on the 4-point Lip Fullness Scale — 93.2 percentage of responders
Acute Mania in Bipolar Disorder
Primary: Change in the Young Mania Rating Scale (YMRS) Total Score From Baseline to Final Assessment (Day 28) — -25.7; -26.1 score on a scale
Niemann-Pick Disease, Type C
Primary: Oxysterol Levels — 28.09; 27.64 ng/mL
Type 2 Diabetes Mellitus
Primary: Number of Participants Who Experienced an Adverse Event During the Study — 46; 21 participants
Ovarian Cancer
Primary: Number of Participants Who Completed a 4-dose Series of Catumaxomab Infusions (Defined as 10-20-50-150 Micrograms) Within 21 Days — 29 Participants
Ciliary Body and Choroid Melanoma, Medium/Large Size · Extraocular Extension Melanoma · Iris Melanoma
Primary: Response Rate (Complete and Partial Response) — 0 participants
Diabetes Mellitus, Type 2
Primary: Number of Participants With Any Clinical Adverse Experience — 18; 16 participants
Recurrent Melanoma · Stage IV Melanoma
Primary: Response Rate (Complete and Partial) — 5; 3 Percent of participants
Lung Cancer · Non Small Cell Lung Cancer
Primary: Progression-free Survival — 4.5 Months
Hantavirus Infections
Primary: The Proportion of Subjects Who Develop Death, PaO2/FiO2 Ratio Less Than or Equal to 55, Cardiac Index Less Than or Equal to 2.2, Pulseless Electrical Activity…
Type 1 Diabetes Mellitus
Primary: Children With T1D Underwent a Single Autologous UCB Transfusion — -0.6 ng /ml /120 min — p=>0.05